Capital Advisors Inc. OK Increases Stake in Intuitive Surgical, Inc. $ISRG

Capital Advisors Inc. OK grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.5% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 122,693 shares of the medical equipment provider’s stock after buying an additional 607 shares during the quarter. Intuitive Surgical accounts for 1.2% of Capital Advisors Inc. OK’s investment portfolio, making the stock its 21st largest holding. Capital Advisors Inc. OK’s holdings in Intuitive Surgical were worth $66,672,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ISRG. Nuveen LLC purchased a new position in Intuitive Surgical during the 1st quarter worth $1,715,899,000. Goldman Sachs Group Inc. raised its position in Intuitive Surgical by 26.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,819,666 shares of the medical equipment provider’s stock worth $1,396,496,000 after buying an additional 584,375 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Intuitive Surgical by 20.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,393,951 shares of the medical equipment provider’s stock worth $1,680,922,000 after buying an additional 566,979 shares during the last quarter. Wellington Management Group LLP raised its position in Intuitive Surgical by 15.0% during the 1st quarter. Wellington Management Group LLP now owns 3,499,052 shares of the medical equipment provider’s stock worth $1,732,975,000 after buying an additional 457,080 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Intuitive Surgical by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 32,665,531 shares of the medical equipment provider’s stock worth $16,178,258,000 after buying an additional 453,335 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ISRG shares. Truist Financial increased their price target on shares of Intuitive Surgical from $590.00 to $600.00 and gave the company a “buy” rating in a report on Wednesday, July 23rd. Zacks Research downgraded shares of Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. UBS Group increased their price target on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a “neutral” rating in a report on Wednesday, July 23rd. Wall Street Zen upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Evercore ISI increased their price target on shares of Intuitive Surgical from $470.00 to $550.00 and gave the company an “in-line” rating in a report on Tuesday, July 8th. Fourteen investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $594.19.

Intuitive Surgical Stock Performance

ISRG opened at $452.35 on Monday. The company’s 50 day simple moving average is $463.55 and its 200 day simple moving average is $500.11. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00. The stock has a market capitalization of $162.16 billion, a PE ratio of 63.09, a P/E/G ratio of 4.74 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business had revenue of $2.44 billion for the quarter, compared to analysts’ expectations of $2.35 billion. During the same period last year, the company earned $1.78 earnings per share. The company’s quarterly revenue was up 21.4% on a year-over-year basis. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, insider Gary S. Guthart sold 29,360 shares of Intuitive Surgical stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the transaction, the insider directly owned 19,827 shares of the company’s stock, valued at $9,368,059.23. The trade was a 59.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of Intuitive Surgical stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the transaction, the executive vice president directly owned 353 shares in the company, valued at approximately $173,845.44. This trade represents a 92.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 45,224 shares of company stock valued at $21,716,492 over the last ninety days. Corporate insiders own 0.70% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.